The DOI matches its Crossref record.
Structural Optimization Affording 2-(R)-(1-(R)-3,5-Bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a Potent, Orally Active, Long-Acting Morpholine Acetal Human NK-1 Receptor Antagonist
Open accessAbstract
Structural modifications requiring novel synthetic chemistry were made to the morpholine acetal human neurokinin-1 (hNK-1) receptor antagonist 4, and this resulted in the discovery of 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-ox o-1 ,2,4-triazol-5-yl)methyl morpholine (17). This modified compound is a potent, long-acting hNK-1 receptor antagonist as evidenced by its ability to displace [125I]Substance P from hNK-1 receptors stably expressed in CHO cells (IC50 = 0.09 +/- 0.06 nM) and by the measurement of the rates of association (k1 = 2.8 +/- 1.1 x 10(8) M-1 min-1) and dissociation (k-1 = 0.0054 +/- 0.003 min-1) of 17 from hNK-1 expressed in Sf9 membranes which yields Kd = 19 +/- 12 pM and a t1/2 for receptor occupancy equal to 154 +/- 75 min. Inflammation in the guinea pig induced by a resiniferatoxin challenge (with NK-1 receptor activation mediating the subsequent increase in vascular permeability) is inhibited in a dose-dependent manner by the oral preadmininstration of 17 (IC50 (1 h) = 0.008 mg/kg; IC90 (24 h) = 1.8 mg/kg), indicating that this compound has good oral bioavailbility and peripheral duration of action. Central hNK-1 receptor stimulation is also inhibited by the systemic preadministration of 17 as shown by its ability to block an NK-1 agonist-induced foot tapping response in gerbils (IC50 (4 h) = 0.04 +/- 0.006 mg/kg; IC50 (24 h) = 0.33 +/- 0.017 mg/kg) and by its antiemetic actions in the ferret against cisplatin challenge. The activity of 17 at extended time points in these preclinical animal models sets it apart from earlier morpholine antagonists (such as 4), and the piperidine antagonists 2 and 3 and could prove to be an advantage in the treatment of chronic disorders related to the actions of Substance P. In part on the basis of these data, 17 has been identified as a potential clinical candidate for the treatment of peripheral pain, migraine, chemotherapy-induced emesis, and various psychiatric disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Fluorine in medicinal chemistry
Purser, S., Moore, P. R., Swallow, S., & Gouverneur, V. (2008) · Chem. Soc. Rev. · doi:10.1039/b610213c · Cited by 7,570
Wang, J., Sánchez-Roselló, M., Aceña, J. L., del Pozo, C., Sorochinsky, A. E., Fustero, S., Soloshonok, V. A., & Liu, H. (2014) · Chemical Reviews · doi:10.1021/cr4002879 · Cited by 4,847
The Many Roles for Fluorine in Medicinal Chemistry
Hagmann, W. K. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800219f · Cited by 3,578
The Combinatorial Synthesis of Bicyclic Privileged Structures or Privileged Substructures
Horton, D. A., Bourne, G. T., & Smythe, M. L. (2003) · Chemical Reviews · doi:10.1021/cr020033s · Cited by 3,013
The medicinal chemist's toolbox for late stage functionalization of drug-like molecules
Cernak, T., Dykstra, K. D., Tyagarajan, S., Vachal, P., & Krska, S. W. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00628g · Cited by 1,743
Green Chemistry in the Synthesis of Pharmaceuticals
Kar, S., Sanderson, H., Roy, K., Benfenati, E., & Leszczynski, J. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00631 · Cited by 566
The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 556
Residence Time of Receptor−Ligand Complexes and Its Effect on Biological Function
Tummino, P. J., & Copeland, R. A. (2008) · Biochemistry · doi:10.1021/bi8002023 · Cited by 544
Long‐lasting target binding and rebinding as mechanisms to prolong in vivo drug action
Vauquelin, G., & Charlton, S. J. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00936.x · Cited by 298
Kourounakis, A. P., Xanthopoulos, D., & Tzara, A. (2020) · Medicinal Research Reviews · doi:10.1002/med.21634 · Cited by 294
Fluorine in Medicinal Chemistry
Swallow, S. (2015) · Progress in Medicinal Chemistry · doi:10.1016/bs.pmch.2014.11.001 · Cited by 280
Meiri, E., Jhangiani, H., Vredenburgh, J. J., Barbato, L. M., Carter, F. J., Yang, H.-M., & Baranowski, V. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x167525 · Cited by 214
Hargreaves, R., Ferreira, J. C. A., Hughes, D., Brands, J., Hale, J., Mattson, B., & Mills, S. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.05961.x · Cited by 102
Self-citation
Metadata
- Authors
- Hale, J. J., Mills, S. G., MacCoss, M., Finke, P. E., Cascieri, M. A., Sadowski, S., Ber, E., Chicchi, G. G., Kurtz, M., Metzger, J., Eiermann, G., Tsou, N. N., Tattersall, F. D., Rupniak, N. M. J., Williams, A. R., Rycroft, W., Hargreaves, R., & MacIntyre, D. E.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1998-10-02
- Volume
- 41
- Issue
- 23
- Pages
- 4607-4614
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2018048919
- Cited by
- 207
- References
- 0
- FWCI
- 2.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.